An overview of bilastine metabolism during preclinical investigations

Drug and Chemical Toxicology

Volumn 35, Issue SUPPL. 1, 2012, Pages 18-24

  Lucero, María Luisa ^a   Gonzalo, Ana ^a   Mumford, Rory ^b   Betanzos, Mónica ^c   Alejandro, Ana ^c  

^a Faes Farma SA   (Spain)

^b CHARLES RIVER LABORATORIES   (United Kingdom)

^c Centro Tecnologico Gaiker   (Spain)

Author keywords

Antihistamines; Bilastine; Drug interactions; Metabolism; Species differences

Indexed keywords

BILASTINE; BILASTINE GLUCURONIDE; CYTOCHROME P450 1A2; CYTOCHROME P450 2A6; CYTOCHROME P450 2B6; CYTOCHROME P450 2C19; CYTOCHROME P450 2C8; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 2E1; CYTOCHROME P450 3A4; DRUG METABOLITE; GLUCURONIDE; HYDROXYBILASTINE; HYDROXYBILASTINE GLUCURONIDE; NORBILASTINE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; CONTROLLED STUDY; DOG; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISPOSITION; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG FECES LEVEL; DRUG GLUCURONIDATION; DRUG METABOLISM; DRUG OXIDATION; DRUG TRANSFORMATION; DRUG URINE LEVEL; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; LIVER MICROSOME METABOLISM; MALE; NONHUMAN; NORMAL HUMAN; RAT; REVIEW; SINGLE DRUG DOSE; SPECIES DIFFERENCE;

ANIMALS; BENZIMIDAZOLES; BIOTRANSFORMATION; DRUG EVALUATION, PRECLINICAL; DRUG INTERACTIONS; HISTAMINE H1 ANTAGONISTS, NON-SEDATING; HUMANS; PIPERIDINES; SPECIES SPECIFICITY;

ANIMALIA;

EID: 84861364955     PISSN: 01480545     EISSN: 15256014     Source Type: Journal    
DOI: 10.3109/01480545.2012.682651     Document Type: Review

References (16)

1. Bachert, C., Kuna, P., Zuberbier, T. (2010). Bilastine in allergicrhinoconjunctivitis and urticaria. Allergy 65(Suppl. 93):1-13.
2. Bousquet, J., Van Cauwenberge, P., Khaltaev, N.; Aria Workshop Group; World Health Organization (2001). Allergic rhinitis and its impact on asthma. J Allergy Clin Immunol 108(Suppl. 5):S147-S334.
3. Church, M. K. (2011). Safety and efficacy of bilastine: a new H1-antihistamine for the treatment of allergic rhinoconjunctivitis and urticaria. Expert Opin Drug Saf 10:779-793.
4. Easterbrook, J., Lu, C., Sakai, Y., Li, A. P. (2001). Effects of organic solvents on the activities of cytochrome P450 isoforms, UDPdependent glucuronyl transferase, and phenol sulfotransferase in human hepatocytes. Drug Metab Dispos 29:141-144. (Pubitemid 32112927)
5. Gonzalo, A., Lucero, M. L. (2008). Identification of processes involved in bilastine bioavailability in rats. Drug Metab Rev 40(Suppl. 1):42.
6. Holgate, S. T., Canonica, G. W., Simons, F. E., Taglialatela, M., Tharp, M., Timmerman, H., et al.; Consensus Group on New-Generation Antihistamines. (2003). Consensus Group on New-Generation Antihistamines (CONGA): present status and recommendations.Clin Exp Allergy 33:1305-1324. (Pubitemid 37108537)
7. Howarth, P. H., Holmberg, K. (1995). Allergic rhinitis an increasing clinical problem. Allergy 50:4-5.
8. Molimard, M., Diquet, B., Benedetti, M. S. (2004). Comparison of the pharmacokinetics and metabolism of deloratadine, fexofenadine, levocetirizine, and mizolastine in humans. Fund Clin Pharmacol 18:399-411. (Pubitemid 39215352)
9. Monahan, B. P., Ferguson, C. L., Killeavy, E. S., Lloyd, B. K., Troy, J., Cantilena, L. R., Jr. (1990). Torsades de pointes occurring in association with terfenadine use. J Am Med Assoc 264:2788-2790.
10. Morag, N., Lucero, M. L., Orjales, A. (2007). In vitro hepatic metabolism of [14C] bilastine. Presented at the 8th International ISSX Meeting, Sendai, Japan, 9-12 Oct 2007. Abstract 160. Drug Metab Rev 39(Suppl. 1):114.
11. Mumford, R., Allan, L., Hoey, R., Patterson, A., Orjales, A., Lucero, M. L., et al. (2007). The disposition, metabolism, and elimination in rats of bilastine, a potent, selective H1 receptor antagonist. Presented at the 8th International ISSX Meeting, Sendai, Japan, 9-12 Oct 2007. Abstract 282. Drug Metab Rev 39 (Suppl. 1):200-201.
12. Renwick, A. G. (1999). The metabolism of antihistamines and drug interactions: the role of cytochrome P450 enzymes. Clin Exp Allergy 29(Suppl. 3):116-124. (Pubitemid 29333345)
13. Sologuren, A., Lucero, M. L., Valiente, R., Charles, H., Mair, S. J. (2009). Human mass balance with [14C]-bilastine following oral administration to healthy volunteers. Presented at the 9th Congress of the European Association for Clinical Pharmacology and Therapeutics, Edinburgh, UK, 12-15 Jul 2009. Abstract TP85. Basic Clin Pharmacol Toxicol 105(Suppl. 1):106-107.
14. Sologuren, A., Valiente, R., Allison, M., Tyl, B. (2008). A lack of significant effect of bilastine on ventricular repolarization. A thorough QT/QTc study. Presented at the XXVII Congress of the European Academy of Allergology and Clinical Immunology, Barcelona, Spain, 7-11 Jun 2008. Abstract 189. Allergy 63(Suppl. 88):85.
15. Tillement, J-P. (2000). The advantages for an H1 antihistamine of a low volume of distribution. Allergy 55(Suppl. 60):17-21. (Pubitemid 30314009)
16. Zambon, S., Fontana, S., Kajbaf, M. (2010). Evaluation of cytochrome P450 inhibition assays using human liver microsomes by a cassette analysis LC-MS/MS. Drug Metab Lett 4:120-128.